Carbidopa/levodopa for smoking cessation: A pilot study with negative results

Richard D. Hurt, J. Eric Ahlskog, Gary A. Croghan, Kenneth P. Offord, Troy D. Wolter, Ivana T Croghan, Thomas P. Moyer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The mesolimbic dopamine system is thought to be a critical substrate for drugs of addiction including nicotine. Since dopamine may play a critical role in mediating the reinforcing effects of nicotine, we hypothesized that administering levodopa in its therapeutic form (carbidopa/levodopa) might be effective for smoking cessation by replacing the effects of dopamine that smokers may seek during smoking. A pilot open-label study using carbidopa/levodopa for smokers wanting to stop smoking was carried out at the Mayo Clinic Nicotine Research Center, Rochester, MN. The dosing schedule was one tablet TID for 1 week, 1 1/2 tablets TID for 1 week, then two tablets TID for 6 weeks. Each tablet contained 25 mg of carbidopa and 100 mg of levodopa. The subjects were 40 adult smokers smoking ≥20 cigarettes per day for 3 or more years. Self-reported abstinence from smoking was confirmed by expired air CO level of ≤8 ppm. Nicotine withdrawal symptoms were assessed at baseline and daily during the medication phase. Smoking abstinence rates and withdrawal symptom relief were compared to the placebo (n=153) arm of a previously reported bupropion smoking cessation trial. The biochemically confirmed, 7-day point-prevalence smoking abstinence rate at the end of carbidopa/levodopa treatment was 20.0% versus 19.0% for the placebo group (p>0.10), and 12.5% of the carbidopa/levodopa group were abstinent versus 15.7% for the placebo group (p>0.10) at 6 months. Subjects from both studies had significant increases in withdrawal scores from baseline, but there were no significant differences between the two groups at any time period. We found no differences in smoking abstinence rates or nicotine withdrawal symptom relief in smokers receiving carbidopa/levodopa compared to placebo. Despite the theoretical reasons why carbidopa/levodopa might be effective as a pharmacological adjunct in treating smokers, it was not observed in this group of smokers at this dose.

Original languageEnglish (US)
Pages (from-to)71-78
Number of pages8
JournalNicotine and Tobacco Research
Volume2
Issue number1
StatePublished - 2000

Fingerprint

Smoking Cessation
Smoking
Nicotine
Substance Withdrawal Syndrome
Tablets
Placebos
Dopamine
Levodopa
Carbidopa
Bupropion
Carbon Monoxide
levodopa drug combination carbidopa
Substance-Related Disorders
Appointments and Schedules
Air
Pharmacology
Therapeutics
Research

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Hurt, R. D., Ahlskog, J. E., Croghan, G. A., Offord, K. P., Wolter, T. D., Croghan, I. T., & Moyer, T. P. (2000). Carbidopa/levodopa for smoking cessation: A pilot study with negative results. Nicotine and Tobacco Research, 2(1), 71-78.

Carbidopa/levodopa for smoking cessation : A pilot study with negative results. / Hurt, Richard D.; Ahlskog, J. Eric; Croghan, Gary A.; Offord, Kenneth P.; Wolter, Troy D.; Croghan, Ivana T; Moyer, Thomas P.

In: Nicotine and Tobacco Research, Vol. 2, No. 1, 2000, p. 71-78.

Research output: Contribution to journalArticle

Hurt, RD, Ahlskog, JE, Croghan, GA, Offord, KP, Wolter, TD, Croghan, IT & Moyer, TP 2000, 'Carbidopa/levodopa for smoking cessation: A pilot study with negative results', Nicotine and Tobacco Research, vol. 2, no. 1, pp. 71-78.
Hurt RD, Ahlskog JE, Croghan GA, Offord KP, Wolter TD, Croghan IT et al. Carbidopa/levodopa for smoking cessation: A pilot study with negative results. Nicotine and Tobacco Research. 2000;2(1):71-78.
Hurt, Richard D. ; Ahlskog, J. Eric ; Croghan, Gary A. ; Offord, Kenneth P. ; Wolter, Troy D. ; Croghan, Ivana T ; Moyer, Thomas P. / Carbidopa/levodopa for smoking cessation : A pilot study with negative results. In: Nicotine and Tobacco Research. 2000 ; Vol. 2, No. 1. pp. 71-78.
@article{e5c1d0afe7e74f3c96a391fcbc5aa681,
title = "Carbidopa/levodopa for smoking cessation: A pilot study with negative results",
abstract = "The mesolimbic dopamine system is thought to be a critical substrate for drugs of addiction including nicotine. Since dopamine may play a critical role in mediating the reinforcing effects of nicotine, we hypothesized that administering levodopa in its therapeutic form (carbidopa/levodopa) might be effective for smoking cessation by replacing the effects of dopamine that smokers may seek during smoking. A pilot open-label study using carbidopa/levodopa for smokers wanting to stop smoking was carried out at the Mayo Clinic Nicotine Research Center, Rochester, MN. The dosing schedule was one tablet TID for 1 week, 1 1/2 tablets TID for 1 week, then two tablets TID for 6 weeks. Each tablet contained 25 mg of carbidopa and 100 mg of levodopa. The subjects were 40 adult smokers smoking ≥20 cigarettes per day for 3 or more years. Self-reported abstinence from smoking was confirmed by expired air CO level of ≤8 ppm. Nicotine withdrawal symptoms were assessed at baseline and daily during the medication phase. Smoking abstinence rates and withdrawal symptom relief were compared to the placebo (n=153) arm of a previously reported bupropion smoking cessation trial. The biochemically confirmed, 7-day point-prevalence smoking abstinence rate at the end of carbidopa/levodopa treatment was 20.0{\%} versus 19.0{\%} for the placebo group (p>0.10), and 12.5{\%} of the carbidopa/levodopa group were abstinent versus 15.7{\%} for the placebo group (p>0.10) at 6 months. Subjects from both studies had significant increases in withdrawal scores from baseline, but there were no significant differences between the two groups at any time period. We found no differences in smoking abstinence rates or nicotine withdrawal symptom relief in smokers receiving carbidopa/levodopa compared to placebo. Despite the theoretical reasons why carbidopa/levodopa might be effective as a pharmacological adjunct in treating smokers, it was not observed in this group of smokers at this dose.",
author = "Hurt, {Richard D.} and Ahlskog, {J. Eric} and Croghan, {Gary A.} and Offord, {Kenneth P.} and Wolter, {Troy D.} and Croghan, {Ivana T} and Moyer, {Thomas P.}",
year = "2000",
language = "English (US)",
volume = "2",
pages = "71--78",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Carbidopa/levodopa for smoking cessation

T2 - A pilot study with negative results

AU - Hurt, Richard D.

AU - Ahlskog, J. Eric

AU - Croghan, Gary A.

AU - Offord, Kenneth P.

AU - Wolter, Troy D.

AU - Croghan, Ivana T

AU - Moyer, Thomas P.

PY - 2000

Y1 - 2000

N2 - The mesolimbic dopamine system is thought to be a critical substrate for drugs of addiction including nicotine. Since dopamine may play a critical role in mediating the reinforcing effects of nicotine, we hypothesized that administering levodopa in its therapeutic form (carbidopa/levodopa) might be effective for smoking cessation by replacing the effects of dopamine that smokers may seek during smoking. A pilot open-label study using carbidopa/levodopa for smokers wanting to stop smoking was carried out at the Mayo Clinic Nicotine Research Center, Rochester, MN. The dosing schedule was one tablet TID for 1 week, 1 1/2 tablets TID for 1 week, then two tablets TID for 6 weeks. Each tablet contained 25 mg of carbidopa and 100 mg of levodopa. The subjects were 40 adult smokers smoking ≥20 cigarettes per day for 3 or more years. Self-reported abstinence from smoking was confirmed by expired air CO level of ≤8 ppm. Nicotine withdrawal symptoms were assessed at baseline and daily during the medication phase. Smoking abstinence rates and withdrawal symptom relief were compared to the placebo (n=153) arm of a previously reported bupropion smoking cessation trial. The biochemically confirmed, 7-day point-prevalence smoking abstinence rate at the end of carbidopa/levodopa treatment was 20.0% versus 19.0% for the placebo group (p>0.10), and 12.5% of the carbidopa/levodopa group were abstinent versus 15.7% for the placebo group (p>0.10) at 6 months. Subjects from both studies had significant increases in withdrawal scores from baseline, but there were no significant differences between the two groups at any time period. We found no differences in smoking abstinence rates or nicotine withdrawal symptom relief in smokers receiving carbidopa/levodopa compared to placebo. Despite the theoretical reasons why carbidopa/levodopa might be effective as a pharmacological adjunct in treating smokers, it was not observed in this group of smokers at this dose.

AB - The mesolimbic dopamine system is thought to be a critical substrate for drugs of addiction including nicotine. Since dopamine may play a critical role in mediating the reinforcing effects of nicotine, we hypothesized that administering levodopa in its therapeutic form (carbidopa/levodopa) might be effective for smoking cessation by replacing the effects of dopamine that smokers may seek during smoking. A pilot open-label study using carbidopa/levodopa for smokers wanting to stop smoking was carried out at the Mayo Clinic Nicotine Research Center, Rochester, MN. The dosing schedule was one tablet TID for 1 week, 1 1/2 tablets TID for 1 week, then two tablets TID for 6 weeks. Each tablet contained 25 mg of carbidopa and 100 mg of levodopa. The subjects were 40 adult smokers smoking ≥20 cigarettes per day for 3 or more years. Self-reported abstinence from smoking was confirmed by expired air CO level of ≤8 ppm. Nicotine withdrawal symptoms were assessed at baseline and daily during the medication phase. Smoking abstinence rates and withdrawal symptom relief were compared to the placebo (n=153) arm of a previously reported bupropion smoking cessation trial. The biochemically confirmed, 7-day point-prevalence smoking abstinence rate at the end of carbidopa/levodopa treatment was 20.0% versus 19.0% for the placebo group (p>0.10), and 12.5% of the carbidopa/levodopa group were abstinent versus 15.7% for the placebo group (p>0.10) at 6 months. Subjects from both studies had significant increases in withdrawal scores from baseline, but there were no significant differences between the two groups at any time period. We found no differences in smoking abstinence rates or nicotine withdrawal symptom relief in smokers receiving carbidopa/levodopa compared to placebo. Despite the theoretical reasons why carbidopa/levodopa might be effective as a pharmacological adjunct in treating smokers, it was not observed in this group of smokers at this dose.

UR - http://www.scopus.com/inward/record.url?scp=0034135821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034135821&partnerID=8YFLogxK

M3 - Article

C2 - 11072443

AN - SCOPUS:0034135821

VL - 2

SP - 71

EP - 78

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 1

ER -